Afatinib Versus Erlotinib in Advanced SCC of the Lung

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

In an interview, Craig A. Portell, MD, offered an in-depth look at sequencing therapies in relapsed/refractory mantle cell lymphoma.